Carolijn de Bresser

Mrs. Carolijn de Bresser


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2024 in Endocrine Pathology
Verified
Journal Article
Open access
PDF file
CBCarolijn de Bresser
Carolijn de Bresser
Ronald de KrijgerRonald de Krijger
Ronald de Krijger
Pheochromocytomas (PCCs) and paragangliomas (PGLs, together PPGLs) are the most hereditary tumors known. PPGLs were considered benign, but the fourth edition of the World Health Organisation (WHO) classification redefined all PPGLs as malignant neoplasms with variable metastatic potential. The metastatic rate differs based on histopathology, genetic background, size, and location of the tumor. The challenge in predicting metastatic disease lies in the absence of a clear genotype–phenotype correlation among the more than 20 identified genetic driver variants. Recent advances in molecular clustering based on underlying genetic alterations have paved the way for improved cluster-specific personalized treatments. However, despite some clusters demonstrating a higher propensity for metastatic disease, cluster-specific therapies have not yet been widely adopted in clinical practice. Comprehensive genomic profiling and transcriptomic analyses of large PPGL cohorts have identified potential new biomarkers that may influence metastatic potential. It appears that no single biomarker alone can reliably predict metastatic risk; instead, a combination of these biomarkers may be necessary to develop an effective prediction model for metastatic disease. This review evaluates current guidelines and recent genomic and transcriptomic findings, with the aim of accurately identifying novel biomarkers that could contribute to a predictive model for mPPGLs, thereby enhancing patient care and outcomes.

28 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CBCarolijn de Bresser
Carolijn de Bresser
BPBart-Jeroen Petri
Bart-Jeroen Petri
ABArthur Johannes Anthonius Theodorus Braat
Arthur Johannes Anthonius Theodorus Braat
BKBart De Keizer
Bart De Keizer
MTMark J. C. van Treijen
Mark J. C. van Treijen
JRJohannes Rijken
Johannes Rijken
The Dutch guideline for patients suspected of head and neck paragangliomas (HNPGLs) recommends magnetic resonance imaging (MRI) and/or computed tomography (CT) of the head and neck area. Additionally, it suggests considering additional nuclear imaging. The aim of this study was to evaluate the outcomes of [68Ga]Ga-DOTATOC PET/CT compared to MRI in patients with suspected HNPGLs and carriers of genetic variations. Methods: In this single-center pilot study, retrospective data were obtained from consecutive patients between 2016 and 2023. Both MRI and [68Ga]Ga-DOTATOC PET/CT were performed within 12 months. The primary outcome was the location of HNPGLs. Results: A total of 25 consecutive patients were included, and 7 patients (28.0%, p = 0.5) showed differences between the imaging modalities, of whom 5 patients had unexpected localizations with additional uptake by somatostatin receptors (SSTR) on the [68Ga]Ga-DOTATOC PET/CT. Conclusions: The authors recommend performing baseline imaging with [68Ga]Ga-DOTATOC PET/CT (if available) in variant carriers and using MRI/CT for follow-up according to the regional protocol, thereby shifting the gold standard for baseline imaging from MRI/CT to [68Ga]Ga-DOTATOC PET/CT.

24 February 2025 in European Journal of Endocrinology
Verified
Journal Article
Open access
CBCarolijn de Bresser
Carolijn de Bresser
JRJohannes A Rijken
Johannes A Rijken
MTMark J C van Treijen
Mark J C van Treijen
BNBernadette P M van Nesselrooij
Bernadette P M van Nesselrooij
MRMischa de Ridder
Mischa de Ridder
RLRachel S van Leeuwaarde
Rachel S van Leeuwaarde
Objective: Autosomal dominant variants in the succinate dehydrogenase gene (SDHx) are responsible for ∼50% of the development of hereditary paragangliomas and pheochromocytomas (PPGLs). Limited research has been conducted on the psychosocial impact of possessing a hereditary tumor syndrome. In this study, the psychological impact of harboring a genetic variant associated with familial paraganglioma syndrome was assessed. Secondary objectives included the analysis of potential variations in quality of life in (pre)symptomatic stage and comparison with the general Dutch population and other hereditary tumor syndromes. Methods: The first 100 patients from the Head and Neck PGL Registry in the University Medical Center Utrecht were selected. Psychosocial outcomes were assessed cross-sectionally using 5 validated health-related questionnaires: EuroQol 5D-5L, Cancer Worry Scale, Hospital Anxiety and Depression Scale, Modified Fatigue Impact Scale, and EORTC QLQ-C30. Results: No significant differences were observed when stratified for (pre)symptomatic status or genetic variant status. Hereditary PPGLs tended to express greater concern about the development of PPGLs in family members. Complaints in the physical domains were more frequently observed in the sporadic group. The PPGL cohort demonstrated better outcomes when compared to other hereditary tumor syndromes and aligned with the Dutch tariff. Conclusion: The psychosocial impact of harboring a PPGL seems to align with the general healthy Dutch population. Clinical care management involving a multidisciplinary approach and comprehensive counseling on PPGLs and their genetic origins, effectively supports patients. Routine psychological support in the care for these patients does not seem imperative and should be offered indicated on a case-by-case basis.

1 January 2026 in European Stroke Journal
Verified
Journal Article
Open access
CBCarolijn de Bresser
Carolijn de Bresser
RWRobbert B M Wiggers
Robbert B M Wiggers
RHRoos A M van Heeswijk
Roos A M van Heeswijk
BMBarend M Mol
Barend M Mol
FKFleur J W Knol
Fleur J W Knol
MPMichiel H F Poorthuis
Michiel H F Poorthuis
Introduction: In meta-analyses of large cohorts, a decline in procedural risks after carotid endarterectomy (CEA) was found. It remains unclear whether these trends extent to smaller cohorts, carotid artery stenting (CAS), and how long-term outcomes have evolved. Patients and methods: PubMed and EMBASE were searched until 18 November 2024, for studies reporting on 100 or more adults undergoing CEA or CAS for symptomatic or asymptomatic carotid stenosis. Primary outcomes were 30-day and long-term risk of stroke or death. We performed separate analyses in smaller cohorts of < 500 patients. Results: 291 studies reported 475,266 patients undergoing CEA (214,526 symptomatic, 260,740 asymptomatic) and 209,117 undergoing CAS (77,133 symptomatic, 131,984 asymptomatic). Short-term stroke or death after CEA declined 36% (RR = 0.64, 95% CI, 0.63–0.64) per 5-year later treatment midyear in symptomatic and 41% (RR = 0.59, 95% CI, 0.59–0.59) in asymptomatic patients, with consistent trends in smaller cohorts.For CAS, short-term risks declined 44% (RR = 0.56, 95% CI, 0.53–0.58) in symptomatic, and 27% (RR = 0.73, 95% CI, 0.71–0.74) in asymptomatic patients, with consistent trends in smaller cohorts. Long-term death risk after CEA increased 26% (RR = 1.26, 95% CI, 1.20–1.32) and 11% in smaller cohorts. Long-term stroke risk after CAS increased 30% (RR = 1.30, 95% CI, 1.17–1.43) and 44% in smaller cohorts. Conclusions: Short-term risks after CEA and CAS have decreased over time, also in smaller cohorts. Long-term death after CEA and stroke after CAS have increased. The increased long-term risk of death after CEA and stroke after CAS limits the durability of carotid interventions and warrants further scrutiny.

25 July 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBCarolijn de Bresser
Carolijn de Bresser
BNBernadette P. M. van Nesselrooij
Bernadette P. M. van Nesselrooij
MTMark J. C. van Treijen
Mark J. C. van Treijen
ABArthur Johannes Anthonius Theodorus Braat
Arthur Johannes Anthonius Theodorus Braat
MRMischa de Ridder
Mischa de Ridder
BPBart-Jeroen Petri
Bart-Jeroen Petri
Introduction: There is a lack of comprehensive and uniform data on head and neck paragangliomas (HNPGLs), and research is challenging due to its rarity and the involvement of multiple medical specialties. To improve current research data collection, we initiated the Head and Neck Paraganglioma Registry (HNPGL Registry). The aim of the HNPGL Registry is to a) collect extensive data on all HNPGL patients through a predefined protocol, b) give insight in the long term outcomes using patient reported outcome measures (PROMs), c) create uniformity in the diagnostic and clinical management of these conditions, and thereby d) help provide content for future (randomized) research. Methods and analysis: The HNPGL Registry is designed as a prospective longitudinal observational registry for data collection on HNPGL patients and carriers of (likely) pathogenic variants causative of HNPGLs. All patients, regardless of the received treatment modality, can be included in the registry after informed consent is obtained. All relevant data regarding the initial presentation, diagnostics, treatment, and follow-up will be collected prospectively in an electronic case report form. In addition a survey containing the EuroQol 5D-5L (EQ-5D-5L), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Modified Fatigue Impact Scale (MFIS), Short QUestionnaire to Assess Health-enhancing physical activity (SQUASH), Cancer Worry Scale (CWS) and Hospital Anxiety and Depression Scale (HADS) will be sent periodically. The registry protocol was approved by the Medical Ethical Review Board of the University Medical Center Utrecht. Conclusion: The HNPGL Registry data will be used to further establish the optimal management for HNPGL patients and lay the foundation for guideline recommendations and the outline of future research.

17 October 2025 in EJVES Vascular Forum
Verified
Journal Article
Open access
OAOumaima Aouam
Oumaima Aouam
CBCarolijn de Bresser
Carolijn de Bresser
EHEline S. van Hattum
Eline S. van Hattum
WFW. Marnix de Fijter
W. Marnix de Fijter
HJHidde Jongsma
Hidde Jongsma
Gert Jan de BorstGert Jan de Borst
Gert Jan de Borst
Free floating thrombus in the carotid artery (cFFT) is a rare and poorly understood condition with an unclear definition and diagnostic criteria. This systematic review aimed to propose a reporting standard to ensure diagnostic consistency and a universal definition of cFFT. PubMed and EMBASE were systematically searched from inception until 01 May 2025, using terms including “free floating thrombus” and “carotid”, along with imaging modalities. Eligibility criteria included studies on patients with cFFT, diagnosed through well defined imaging criteria. Two authors independently screened eligible literature and extracted data. Study quality was assessed with the Methodological Index for Non-Randomized Studies (MINORS) score. The composite endpoint was the radiological description of cFFT per imaging modality. A systematic search identified 611 publications, from which 20 were included. These studies were predominantly of low quality, with a mean MINORS score of 9 for non-comparative and 16 for comparative studies. These 20 studies identified 17 distinct imaging based descriptions of cFFT. The descriptions were derived from five different imaging modalities, encompassing both static and dynamic imaging. Computed tomography angiography (CTA) was the most reported modality, followed by duplex ultrasound (DUS). On CTA, cFFT is diagnosed as a thrombus with circumferential flow, proximal attachment to the vessel wall, and extending distally in the lumen. On DUS, cFFT is diagnosed by circumferential flow, attachment to the arterial wall, and synchronous movement with the cardiac cycle. The published literature lacks high quality studies. It is suggested that the diagnosis of cFFT requires static imaging, preferably with CTA. If static imaging is inconclusive, a dedicated dynamic assessment by DUS, performed by an experienced sonographer, is suggested. The proposed definition aims to standardise the diagnostic workflow for cFFT, thereby ensuring consistent interpretation and unified terminology across research and clinical practice, which should also enhance individual patient data meta-analyses on cFFT in the future.